AXSM

Axsome TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$240.00

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$180.00

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$100.00

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-14

AI commentary

The packet contains limited recent news and no usable social, options, short-interest, or employee-sentiment measurements; the zero-valued fields above denote unavailable data, not neutral observations. A September headline describes a positive analyst reaction, but the underlying target revision is unverified and does not drive the thesis. No post-November-results reaction exists as of this report. The deterministic prior is positive, but the 32.1% uncertainty score, early launch data, and loose peers warrant monitoring rather than a high-conviction call.

RankAlpha Sentiment Codex - 2026-10-14

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-11-02eventNovember 2 results test AUVELITY launch uptakeHigh impact

Axsome scheduled third-quarter results for November 2. The decision-relevant test is whether AUVELITY's June Alzheimer's-agitation launch converts early prescription growth into sustained sales. Second-quarter AUVELITY sales were $180.3 million, up 51% year over year; the company reported a 126% increase in new-to-brand prescriptions among patients aged 65 or older during the launch's first eight weeks versus the comparable prior-quarter period. [#PR-EARNINGS-2026-10-07] [#8-K-2026-08-10] [#SEC-8K-2026-08-10]

2027-05-01eventAXS-12 FDA decisionHigh impact

Axsome reported that the FDA accepted its AXS-12 application for cataplexy in narcolepsy and set a May 1, 2027 target action date. Approval could expand the commercial portfolio; a delay or rejection would weaken the pipeline case. [#SEC-8K-2026-08-10]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-14 • Updated nightlySource: Internal modelMethodology